Introduction
We utilize blood or tissue specimens to determine if patients with ovarian cancer, prostate cancer, or other malignancies carry pathogenic or likely pathogenic variants in the BRCA1/2 genes. This assists physicians in assessing the patient's eligibility for treatment with PARP inhibitors.
Features / strengths
1. International Standards, Local Services
2. National Laboratory Quality Certification
3. Using NGS Leading Technology
4. Fast and Accurate Report Issuance
5. Complete Clinical Trial Basis
Specification in detail
Specimen Type
Blood, FFPE
